BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 15852216)

  • 1. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P2 receptors in platelet function.
    Hechler B; Cattaneo M; Gachet C
    Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The platelet P2 receptors in thrombosis.
    Gachet C; Hechler B
    Semin Thromb Hemost; 2005 Apr; 31(2):162-7. PubMed ID: 15852219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet activation by ADP: the role of ADP antagonists.
    Gachet C
    Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the P2 receptors.
    Boeynaems JM; Communi D; Gonzalez NS; Robaye B
    Semin Thromb Hemost; 2005 Apr; 31(2):139-49. PubMed ID: 15852217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors.
    Baurand A; Eckly A; Bari N; Léon C; Hechler B; Cazenave JP; Gachet C
    Thromb Haemost; 2000 Sep; 84(3):484-91. PubMed ID: 11019976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
    Bal Dit Sollier C; Berge N; Boval B; Hovsepian L; Drouet L
    Thromb Haemost; 2009 Jan; 101(1):116-22. PubMed ID: 19132197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deaggregation is an integral component of the response of platelets to ADP in vitro: kinetic studies of literature and original data.
    Maayani S; Tagliente TM; Schwarz T; Craddock-Royal B; Alcala C; Marrero G; Martinez R
    Platelets; 2001 Aug; 12(5):279-91. PubMed ID: 11487380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
    Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
    J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The P2 receptors and congenital platelet function defects.
    Cattaneo M
    Semin Thromb Hemost; 2005 Apr; 31(2):168-73. PubMed ID: 15852220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2Y receptor antagonists in thrombosis.
    Boeynaems JM; van Giezen H; Savi P; Herbert JM
    Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase.
    Boyer JL; Lazarowski ER; Chen XH; Harden TK
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1140-6. PubMed ID: 8263774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel.
    Hechler B; Eckly A; Ohlmann P; Cazenave JP; Gachet C
    Br J Haematol; 1998 Dec; 103(3):858-66. PubMed ID: 9858246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet P2Y₁₂ receptor inhibition: an update on clinical drug development.
    Vivas D; Angiolillo DJ
    Am J Cardiovasc Drugs; 2010; 10(4):217-26. PubMed ID: 20653328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation.
    Léon C; Vial C; Gachet C; Ohlmann P; Hechler B; Cazenave JP; Lecchi A; Cattaneo M
    Thromb Haemost; 1999 May; 81(5):775-81. PubMed ID: 10365753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
    Foster CJ; Prosser DM; Agans JM; Zhai Y; Smith MD; Lachowicz JE; Zhang FL; Gustafson E; Monsma FJ; Wiekowski MT; Abbondanzo SJ; Cook DN; Bayne ML; Lira SA; Chintala MS
    J Clin Invest; 2001 Jun; 107(12):1591-8. PubMed ID: 11413167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.